ArticleJournal of inflammation research2021
Inflammatory Factors as Potential Markers of Early Neurological Deterioration in Acute Ischemic Stroke Patients Receiving Endovascular Therapy - The AISRNA Study.
Article in Journal of inflammation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04175691 (Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Neutrophil-to-Lymphocyte Ratio and Early Neurological Deterioration in Stroke Patients: A Systematic Review and Meta-Analysis.BioMed research international · 2022Pooled it
- Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke.Journal of the American Heart Association · 2025Trial
- Effects of edaravone dexborneol on functional outcome and inflammatory response in patients with acute ischemic stroke.BMC neurology · 2024Trial
- Efficacy and Safety of an Early Aggressive Lipid-Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy.CNS drugs · 2026Article
- Exosomal Protein Biomarkers for Predicting Early Neurological Deterioration Following Intravenous Thrombolysis in Acute Ischemic Stroke.Translational stroke research · 2026Article
- Interleukin‑6 and ischemic stroke: From mechanisms to clinical prospects (Review).Molecular medicine reports · 2026Review
- Predicting early neurological deterioration in acute branch atheromatous disease without reperfusion therapy: a machine learning model.Frontiers in neuroscience · 2026Article
- Serum IL-6 and functional outcome after endovascular therapy: the mediating role of infarct volume growth in acute ischemic stroke.Frontiers in immunology · 2026Article
- Serum inflammatory cytokines predict 90-day outcome after endovascular treatment in acute ischemic stroke.Frontiers in neurology · 2026Article
- Analyzing the serum biochemical factors that influence early neurological deterioration in ischemic Stroke patients and developing a nomogram prediction model.Journal of medical biochemistry · 2025Article
- Assembling the RNA therapeutics toolbox.Medical review (2021) · 2024Review
- Inflammatory marker profiles and in-hospital neurological deterioration in patients with acute minor ischemic stroke.CNS neuroscience & therapeutics · 2024Article
- Body fluids biomarkers associated with prognosis of acute ischemic stroke: progress and prospects.Future science OA · 2024Review
- Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study.Therapeutic advances in neurological disorders · 2023Article
- New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress.Medicina (Kaunas, Lithuania) · 2022Article
- A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke.Frontiers in aging neuroscience · 2022Review
- Predictors of Early Neurological Deterioration and Functional Outcome in Acute Ischemic Stroke: The Importance of Large Artery Disease, Hyperglycemia and Inflammatory Blood Biomarkers.Neuropsychiatric disease and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThis study aimed to explore several peripheral blood-based markers related to the inflammatory response in a total of 210 patients with acute ischemic stroke (AIS) caused by large artery occlusion in the anterior circulation who received endovascular therapy (EVT) from an observational study of clinical significance of circulating non-coding RNA in acute ischemic stroke (AISRNA).
methodsWe collected baseline characteristics of 210 AIS patients participating in an observational acute stroke cohort: the AISRNA study. The following inflammatory factors were measured in these participants: interleukin-2 [IL-2], IL-4, IL-6, IL-10, tumor necrosis factor-α [TNF-α], and interferon-γ [IFN-γ]. The National Institute of Health Stroke Scale score increase of ≥4 within 24 hours after EVT defined as early neurological deterioration (END).
resultsCompared with patients without END, patients with END had a higher incidence of atrial fibrillation (
conclusionIL-6 and IL-10 levels at admission may be potential markers of END after EVT, and the time course of IL-4, IL-6, and IL-10 is correlated with stroke progression. Further larger studies are needed to confirm the current findings.
trial registrationClinicalTrials.gov NCT04175691. Registered November 21, 2019, https://www.clinicaltrials.gov/ct2/show/NCT04175691.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.